-
Neuroprotective effects of niclosamide on disease progression via inflammatory pathways modulation in SOD1-G93A and FUS-associated amyotrophic lateral sclerosis models Neurotherapeutics (IF 5.7) Pub Date : 2024-03-15 Martina Milani, Ilaria Della Valle, Simona Rossi, Paola Fabbrizio, Cassandra Margotta, Giovanni Nardo, Mauro Cozzolino, Nadia D'Ambrosi, Savina Apolloni
Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disease influenced by genetic, epigenetic, and environmental factors, resulting in dysfunction in cellular and molecular pathways. The limited efficacy of current treatments highlights the need for combination therapies targeting multiple aspects of the disease. Niclosamide, an anthelminthic drug listed as an essential medicine, has
-
Effectiveness analysis of three-drug combination therapies for refractory focal epilepsy Neurotherapeutics (IF 5.7) Pub Date : 2024-03-15 Chunmei Wu, Huiting Wu, Yingying Zhou, Xiaoyan Liu, Shanshan Huang, Suiqiang Zhu
Selecting appropriate antiseizure medications (ASMs) for combination therapy in patients with drug-resistant epilepsy (DRE) is a complex task that requires an empirical approach, especially in patients receiving polytherapy. We aimed to analyze the effectiveness of various three-drug combinations in a group of patients with DRE under real-world conditions. This single-center, longitudinal observational
-
Application of targeted liposomes-based salvianolic acid A for the treatment of ischemic stroke Neurotherapeutics (IF 5.7) Pub Date : 2024-03-15 Ming-Yan Yang, Yu Liu, Ya-Wen Yu, Bai-Fang Gong, Jian Ruan, Hua-Ying Fan
Novel therapeutics for the treatment of ischemic stroke remains to be the unmet clinical needs. Previous studies have indicated that salvianolic acid A (SAA) is a promising candidate for the treatment of the brain diseases. However, SAA has poor absolute bioavailability and does not efficiently cross the intact blood-brain barrier (BBB), which limit its efficacy. To this end we developed a brain-targeted
-
Neuroprotective efficacy of hypothermia and Inter-alpha Inhibitor Proteins after hypoxic ischemic brain injury in neonatal rats Neurotherapeutics (IF 5.7) Pub Date : 2024-03-06 Xiaodi F. Chen, Yuqi Wu, Boram Kim, Kevin V. Nguyen, Ainuo Chen, Joseph Qiu, Andre R. Santoso, Clemence Disdier, Yow-Pin Lim, Barbara S. Stonestreet
Therapeutic hypothermia is the standard of care for hypoxic-ischemic (HI) encephalopathy. Inter-alpha Inhibitor Proteins (IAIPs) attenuate brain injury after HI in neonatal rats. Human (h) IAIPs (60 mg/kg) or placebo (PL) were given 15 min, 24 and 48 h to postnatal (P) day-7 rats after carotid ligation and 8% oxygen for 90 min with (30 °C) and without (36 °C) exposure to hypothermia 1.5 h after
-
Honokiol hexafluoro confers reversal of neuropathological markers of HIV infection in a murine SCID model Neurotherapeutics (IF 5.7) Pub Date : 2024-02-22 Zhan Zhang, Aaron Scanlan, Rajeth Koneru, Chelsea Richardson Morrell, Monica D. Reece, Emily Edwards, Sebastian Roa, Christina Gavegnano, Heather Bimonte-Nelson, Jack Arbiser, William Tyor
Cognitive impairment remains a persistent challenge in people living with HIV (PWLH) despite antiretroviral therapy (ART) due to ART's inability to eliminate brain HIV. HIV-induced cognitive dysfunction results from immune dysregulation, ongoing neuroinflammation, and the continuous virus presence, collectively contributing to cognitive deficits. Therefore, adjunctive therapies are needed to reduce
-
Ultrahigh frequency transcutaneous electrical nerve stimulation for neuropathic pain alleviation and neuromodulation Neurotherapeutics (IF 5.7) Pub Date : 2024-02-16 Szu-Han Chen, Yu-Wen Lin, Wan-Ling Tseng, Wei-Tso Lin, Sheng-Che Lin, Yuan-Yu Hsueh
A challenging complication in patients with peripheral compressive neuropathy is neuropathic pain. Excessive neuroinflammation at the injury site worsens neuropathic pain and impairs function. Currently, non-invasive modulation techniques like transcutaneous electrical nerve stimulation (TENS) have shown therapeutic promise with positive results. However, the underlying regulatory molecular mechanism
-
Efficacy of therapy by MK-28 PERK activation in the Huntington's disease R6/2 mouse model Neurotherapeutics (IF 5.7) Pub Date : 2024-02-16 Talya Shacham, Daniel Offen, Gerardo Z. Lederkremer
There is currently no disease-modifying therapy for Huntington's disease (HD). We recently described a small molecule, MK-28, which restored homeostasis in HD models by specifically activating PKR-like ER kinase (PERK). This activation boosts the unfolded protein response (UPR), thereby reducing endoplasmic reticulum (ER) stress, a central cytotoxic mechanism in HD and other neurodegenerative diseases
-
Neurophysiological treatment effects of mesdopetam, pimavanserin and clozapine in a rodent model of Parkinson's disease psychosis Neurotherapeutics (IF 5.7) Pub Date : 2024-02-16 Tiberiu Loredan Stan, Abdolaziz Ronaghi, Sebastian A. Barrientos, Pär Halje, Luciano Censoni, Emilio Garro-Martínez, Azat Nasretdinov, Evgenya Malinina, Stephan Hjorth, Peder Svensson, Susanna Waters, Kristoffer Sahlholm, Per Petersson
Psychosis in Parkinson's disease is a common phenomenon associated with poor outcomes. To clarify the pathophysiology of this condition and the mechanisms of antipsychotic treatments, we have here characterized the neurophysiological brain states induced by clozapine, pimavanserin, and the novel prospective antipsychotic mesdopetam in a rodent model of Parkinson's disease psychosis, based on chronic
-
Repetitive transcranial magnetic stimulation as a treatment for Alzheimer's disease: A randomized placebo-controlled double-blind clinical trial Neurotherapeutics (IF 5.7) Pub Date : 2024-02-14 Zahra Moussavi, Maria Uehara, Grant Rutherford, Brian Lithgow, Colleen Millikin, Xikui Wang, Chandan Saha, Behzad Mansouri, Craig Omelan, Lesley Fellows, Paul B. Fitzgerald, Lisa Koski
-
Focused ultrasound stimulation of infralimbic cortex attenuates reinstatement of methamphetamine-induced conditioned place preference in rats Neurotherapeutics (IF 5.7) Pub Date : 2024-02-13 Chia-Wei Lin, Min-Hsuan Cheng, Ching-Hsiang Fan, Hwei-Hsien Chen, Chih-Kuang Yeh
Methamphetamine (MA) use disorder poses significant challenges to both the affected individuals and society. Current non-drug therapies like transcranial direct-current stimulation and transcranial magnetic stimulation have limitations due to their invasive nature and limited reach to deeper brain areas. Transcranial focused ultrasound (FUS) is gaining attention as a noninvasive option with precise
-
The relationship between atrial cardiopathy biomarkers and prognosis of patients with acute ischemic stroke after endovascular treatment Neurotherapeutics (IF 5.7) Pub Date : 2024-02-05 Yixin Zhao, Yuye Ning, Lei Lei, Qin Liu, Mengmeng Li, Xiangyu Lei, Wanying Chen, Yiting Hu, Ting Xie, Jiaxin Luan, Haoyu Yang, Guogang Luo
Thromboembolism is a possible consequence of underlying atrial cardiopathy, which can occur even before the onset of atrial fibrillation. Our objective was to examine the association between biomarkers of atrial cardiopathy and outcomes of acute ischemic stroke (AIS) following endovascular treatment (EVT). We conducted a retrospective study that collected data from patients with AIS who underwent EVT
-
Cannabidiol reduces intraventricular hemorrhage brain damage, preserving myelination and preventing blood brain barrier dysfunction in immature rats Neurotherapeutics (IF 5.7) Pub Date : 2024-02-01 Aarón Del Pozo, María de Hoz-Rivera, Angela Romero, María Villa, María Martínez, Laura Silva, Fabiana Piscitelli, Vincenzo Di Marzo, Ana Gutiérrez-Rodríguez, William Hind, José Martínez-Orgado
-
The mechanistic divide in psychedelic neuroscience: An unbridgeable gap? Neurotherapeutics (IF 5.7) Pub Date : 2024-01-25 Bryan R. Barksdale, Manoj K. Doss, Gregory A. Fonzo, Charles B. Nemeroff
In recent years, psychedelics have generated considerable excitement and interest as potential novel therapeutics for an array of conditions, with the most advanced evidence base in the treatment of certain severe and/or treatment-resistant psychiatric disorders. An array of clinical and pre-clinical evidence has informed our current understanding of how psychedelics produce profound alterations in
-
Disentangling tau: One protein, many therapeutic approaches Neurotherapeutics (IF 5.7) Pub Date : 2024-01-25 Courtney Lane-Donovan, Adam L. Boxer
The tauopathies encompass over 20 adult neurodegenerative diseases and are characterized by the dysfunction and accumulation of insoluble tau protein. Among them, Alzheimer's disease, frontotemporal dementia, and progressive supranuclear palsy collectively impact millions of patients and their families worldwide. Despite years of drug development using a variety of mechanisms of action, no therapeutic
-
Pink1 deficiency enhances neurological deficits and inflammatory responses after intracerebral hemorrhage in mice Neurotherapeutics (IF 5.7) Pub Date : 2024-01-23 Jingchen Li, Jianliang Li, Erkun Guo, Yuanyu Wang, Ming Yang, Haoran Huo, Yunpeng Shi, Lin Zhao
Pink1 (PTEN-induced putative kinase 1) is a protein associated with maintaining mitochondrial function and integrity and has been reported to mediate neurodegeneration and neuroinflammation. While the role of Pink1 in intracerebral hemorrhage (ICH)-related neurological deficits and inflammatory responses is not deciphered. Congenic blood was transfused into the left corpus striatum to construct the
-
Evidence of mirror therapy for recruitment of ipsilateral motor pathways in stroke recovery: A resting fMRI study Neurotherapeutics (IF 5.7) Pub Date : 2024-01-22 Kexu Zhang, Li Ding, Xu Wang, Jinyang Zhuang, Shanbao Tong, Jie Jia, Xiaoli Guo
Mirror therapy (MT) has been proposed to promote motor recovery post-stroke through activation of mirror neuron system, recruitment of ipsilateral motor pathways, or/and increasing attention toward the affected limb. However, neuroimaging evidence for these mechanisms is still lacking. To uncover the underlying mechanisms, we designed a randomized controlled study and used a voxel-based whole-brain
-
ICA-27243 improves neuromuscular function and preserves motoneurons in the transgenic SOD1G93A mice Neurotherapeutics (IF 5.7) Pub Date : 2024-01-22 Vera M. Masegosa, Xavier Navarro, Mireia Herrando-Grabulosa
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by the death of upper and lower motor neurons (MNs). Excessive neuronal excitability has been implicated in MN degeneration; thus, modulation of hyperexcitability appears as a promising therapeutic strategy. Potassium channels are attractive targets since they can be activated at subthreshold voltages and can
-
Calcitriol ameliorates motor deficits and prolongs survival of Chrne-deficient mouse, a model for congenital myasthenic syndrome, by inducing Rspo2 Neurotherapeutics (IF 5.7) Pub Date : 2024-01-16 Bisei Ohkawara, Hiroyuki Tomita, Taro Inoue, Shaochuan Zhang, Shunsuke Kanbara, Hiroyuki Koshimizu, Yuki Miyasaka, Jun-ichi Takeda, Hiroshi Nishiwaki, Hiroaki Nakashima, Mikako Ito, Akio Masuda, Naoki Ishiguro, Tomoo Ogi, Tamio Ohno, Shiro Imagama, Kinji Ohno
-
Recombinant soluble form of receptor for advanced glycation end products ameliorates microcirculation impairment and neuroinflammation after subarachnoid hemorrhage Neurotherapeutics (IF 5.7) Pub Date : 2024-01-04 Ling-Yu Yang, Sung-Chun Tang, Jing-Er Lee, Yong-Ren Chen, Yi-Tzu Chen, Kuo-Wei Chen, Sung-Tsang Hsieh, Kuo-Chuan Wang
Impaired cerebral microcirculation after subarachnoid hemorrhage (SAH) has been shown to be related to delayed ischemic neurological deficits (DIND). We previously demonstrated the involvement of the receptor for advanced glycation end products (RAGE) in the pathogenesis of SAH related neuronal death. In the present study, we aimed to investigate the therapeutic effects of a recombinant soluble form
-
Humoral and T-cell response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients: Correlations with DMTs and clinical variables Neurotherapeutics (IF 5.7) Pub Date : 2023-12-19 Stefania Barone, Camillo Palmieri, Luca Gallelli, Vincenzo Rania, Angelo Pascarella, Antonio Abatino, Pietro Antonio Bruno, Alessandro Casarella, Marilisa Pasquale, Lucia Manzo, Giovambattista De Sarro, Antonio Gambardella, Paola Valentino
Disease-modifying therapies (DMTs) can affect vaccine responses in individuals with multiple sclerosis (MS). We assessed the humoral and T-cell responses following SARS-CoV-2 mRNA vaccination in MS patients receiving various DMTs. We prospectively enrolled 243 participants, including 113 healthy control subjects and 130 MS patients. Blood samples for detecting SARS-CoV-2 antibodies were collected at
-
Inhibition of aquaporin-4 and its subcellular localization attenuates below-level central neuropathic pain by regulating astrocyte activation in a rat spinal cord injury model Neurotherapeutics (IF 5.7) Pub Date : 2023-12-19 Yu Song, Tao Xue, Shiwu Guo, Zhen Yu, Chengming Yun, Jie Zhao, Zhiwen Song, Zhiyuan Liu
The mechanisms of central neuropathic pain (CNP) caused by spinal cord injury have not been sufficiently studied. We have found that the upregulation of astrocytic aquaporin-4 (AQP4) aggravated peripheral neuropathic pain after spinal nerve ligation in rats. Using a T13 spinal cord hemisection model, we showed that spinal AQP4 was markedly upregulated after SCI and mainly expressed in astrocytes in
-
Canagliflozin ameliorates neuronal injury after cerebral ischemia reperfusion by targeting SGLT1 and AMPK-dependent apoptosis Neurotherapeutics (IF 5.7) Pub Date : 2023-12-19 Zhaoxu Zheng, Xiheng Chen, Yisen Zhang, Ying Zhang, Kun Wang, Zhongfang Shi, Xinjian Yang, Fang Yuan, Jian Liu
Currently, the treatment of acute ischemic stroke is still limited. In clinical studies, the effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on stroke risk is controversial. This preclinical study was conducted to determine whether canagliflozin, a SGLT2 inhibitor, has neuroprotective effects on ischemic stroke and the underlying mechanisms. The middle cerebral artery occlusion (MCAO) model
-
Assessing Sustained B-Cell Depletion and Disease Activity in a French Multiple Sclerosis Cohort Treated by Long-Term IV Anti-CD20 Antibody Therapy Neurotherapeutics (IF 5.7) Pub Date : 2023-10-26 Sean A. Freeman, Bruno Lemarchant, Tifanie Alberto, Julie Boucher, Olivier Outteryck, Myriam Labalette, Stéphanie Rogeau, Sylvain Dubucquoi, Hélène Zéphir
-
Arterial Glyceryl Trinitrate in Acute Ischemic Stroke After Thrombectomy for Neuroprotection (AGAIN): A Pilot Randomized Controlled Trial Neurotherapeutics (IF 5.7) Pub Date : 2023-10-24 Zhe Cheng, Jie Gao, Yuchuan Ding, Qi Pang, Gary B. Rajah, Xiaokun Geng
-
Magnetic Resonance-Guided Focused Ultrasound Thalamotomy Rebalances Atypical Functional Hierarchy in Patients with Essential Tremor Neurotherapeutics (IF 5.7) Pub Date : 2023-10-16 Jiaji Lin, Xiaopeng Kang, Haoxuan Lu, Dekang Zhang, Xianbing Bian, Jiayou Zhou, Jianxing Hu, Dong Zhang, Jorge Sepulcre, Longsheng Pan, Xin Lou
-
Intravenous Administration of an AAV9 Vector Ubiquitously Expressing C1orf194 Gene Improved CMT-Like Neuropathy in C1orf194-/- Mice Neurotherapeutics (IF 5.7) Pub Date : 2023-10-16 Zongrui Shen, Meiyi Li, Fei He, Cheng Huang, Yingchun Zheng, Zhikui Wang, Shunfei Ma, Li Chen, Zhengshan Liu, Hui Zheng, Fu Xiong
-
Transforming Drug Development for Neurological Disorders: Proceedings from a Multidisease Area Workshop Neurotherapeutics (IF 5.7) Pub Date : 2023-10-12 Diane Stephenson, Ramona Belfiore-Oshan, Yashmin Karten, Jessi Keavney, D. Kevin Kwok, Terina Martinez, Joe Montminy, Martijn L. T. M. Müller, Klaus Romero, Sudhir Sivakumaran
-
Wavelet-Based Bracketing, Time–Frequency Beta Burst Detection: New Insights in Parkinson’s Disease Neurotherapeutics (IF 5.7) Pub Date : 2023-10-11 Tanmoy Sil, Ibrahem Hanafi, Hazem Eldebakey, Chiara Palmisano, Jens Volkmann, Muthuraman Muthuraman, Martin M. Reich, Robert Peach
-
D1R-5-HT2AR Uncoupling Reduces Depressive Behaviours via HDAC Signalling Neurotherapeutics (IF 5.7) Pub Date : 2023-10-02 Weifen Li, Tahir Ali, Shengnan Mou, Qichao Gong, Ningning Li, Liangliang Hao, Zhi-Jian Yu, Shupeng Li
-
Therapeutic Effects of Combination of Nebivolol and Donepezil: Targeting Multifactorial Mechanisms in ALS Neurotherapeutics (IF 5.7) Pub Date : 2023-10-02 Soo Yeon Lee, Hye-Yeon Cho, Jung-Pyo Oh, Jiae Park, Sang-Hun Bae, Haesun Park, Eun Jung Kim, Ji-Hyun Lee
-
Should Age 65 be a cutoff for Primary Progressive Multiple Sclerosis therapy? Real World Data is Critical. Neurotherapeutics (IF 5.7) Pub Date : 2023-10-04 P K Coyle
-
Letter from the Editor-in-Chief: Neurotherapeutics' Transition to Gold Open Access. Neurotherapeutics (IF 5.7) Pub Date : 2023-10-01 M Maral Mouradian
-
Pharmacotherapy for Traumatic Brain Injury: The Next Generation of Clinical Trials. Neurotherapeutics (IF 5.7) Pub Date : 2023-10-01 Ramon Diaz-Arrastia,Patrick M Kochanek
-
Recombinant Erythropoietin Induces Oligodendrocyte Progenitor Cell Proliferation After Traumatic Brain Injury and Delayed Hypoxemia Neurotherapeutics (IF 5.7) Pub Date : 2023-09-28 Kirill Shumilov, Sophia Xiao, Allen Ni, Marta Celorrio, Stuart H. Friess
-
The Renin Angiotensin System as a Therapeutic Target in Traumatic Brain Injury Neurotherapeutics (IF 5.7) Pub Date : 2023-09-27 Sonia Villapol, Zachary C. Janatpour, Kwame O. Affram, Aviva J. Symes
-
Optimized Nutrition in Mitochondrial Diseases Correlates with Improved Muscle Fatigue, Strength, and Quality of Life: You Are What You Eat, or Are You? Neurotherapeutics (IF 5.7) Pub Date : 2023-09-28 Russell P Saneto,Amel Karaa
-
Persistent NRG1 Type III Overexpression in Spinal Motor Neurons Has No Therapeutic Effect on ALS-Related Pathology in SOD1G93A Mice Neurotherapeutics (IF 5.7) Pub Date : 2023-09-21 Sara Hernández, Sara Salvany, Anna Casanovas, Lídia Piedrafita, M. Clara Soto-Bernardini, Olga Tarabal, Alba Blasco, Sílvia Gras, Alaó Gatius, Markus H. Schwab, Jordi Calderó, Josep E. Esquerda
-
Optimized Nutrition in Mitochondrial Disease Correlates to Improved Muscle Fatigue, Strength, and Quality of Life Neurotherapeutics (IF 5.7) Pub Date : 2023-09-18 Donna DiVito, Amanda Wellik, Jessica Burfield, James Peterson, Jean Flickinger, Alyssa Tindall, Kimberly Albanowski, Shailee Vishnubhatt, Laura MacMullen, Isaac Martin, Colleen Muraresku, Elizabeth McCormick, Ibrahim George-Sankoh, Shana McCormack, Amy Goldstein, Rebecca Ganetzky, Marc Yudkoff, Rui Xiao, Marni J. Falk, Maria R. Mascarenhas, Zarazuela Zolkipli-Cunningham
-
Paradigm Shift: Multiple Potential Pathways to Neurodegenerative Dementia Neurotherapeutics (IF 5.7) Pub Date : 2023-09-21 Amalia Perna, Kathleen S. Montine, Lon R. White, Thomas J. Montine, Brenna A. Cholerton
-
Frequency-Dependent Reduction of Cybersickness in Virtual Reality by Transcranial Oscillatory Stimulation of the Vestibular Cortex Neurotherapeutics (IF 5.7) Pub Date : 2023-09-18 Alberto Benelli, Francesco Neri, Alessandra Cinti, Patrizio Pasqualetti, Sara M. Romanella, Alessandro Giannotta, David De Monte, Marco Mandalà, Carmelo Smeralda, Domenico Prattichizzo, Emiliano Santarnecchi, Simone Rossi
-
Treating Traumatic Brain Injury with Minocycline Neurotherapeutics (IF 5.7) Pub Date : 2023-09-18 Peter J. Bergold, Rachel Furhang, Siobhán Lawless
-
Gys1 Antisense Therapy Prevents Disease-Driving Aggregates and Epileptiform Discharges in a Lafora Disease Mouse Model Neurotherapeutics (IF 5.7) Pub Date : 2023-09-12 Katherine J. Donohue, Bethany Fitzsimmons, Ronald C. Bruntz, Kia H. Markussen, Lyndsay E. A. Young, Harrison A. Clarke, Peyton T. Coburn, Laiken E. Griffith, William Sanders, Jack Klier, Sara N. Burke, Andrew P. Maurer, Berge A. Minassian, Ramon C. Sun, Holly B. Kordasiewisz, Matthew S. Gentry
-
Phosphodiesterase-5 (PDE-5) Inhibitors as Therapy for Cerebrovascular Dysfunction in Chronic Traumatic Brain Injury Neurotherapeutics (IF 5.7) Pub Date : 2023-09-11 Priyanka Kalyani, Sara M. Lippa, J. Kent Werner, Franck Amyot, Carol B. Moore, Kimbra Kenney, Ramon Diaz-Arrastia
-
Functional Brain Networks to Evaluate Treatment Responses in Parkinson’s Disease Neurotherapeutics (IF 5.7) Pub Date : 2023-09-08 János A. Barbero, Prashin Unadkat, Yoon Young Choi, David Eidelberg
-
Evolving Therapeutic Options for the Treatment of Duchenne Muscular Dystrophy Neurotherapeutics (IF 5.7) Pub Date : 2023-09-06 Eleonora S. D’Ambrosio, Jerry R. Mendell
-
Application of P7C3 Compounds to Investigating and Treating Acute and Chronic Traumatic Brain Injury Neurotherapeutics (IF 5.7) Pub Date : 2023-08-31 Preethy S. Sridharan, Emiko Miller, Andrew A. Pieper
-
Neurosteroid Receptor Modulators for Treating Traumatic Brain Injury Neurotherapeutics (IF 5.7) Pub Date : 2023-08-31 Todd A. Verdoorn, Tom J. Parry, Graziano Pinna, Jonathan Lifshitz
-
An Understated Comorbidity: The Impact of Homelessness on Traumatic Brain Injury Neurotherapeutics (IF 5.7) Pub Date : 2023-08-28 M. Monsour, J.-Y. Lee, C.V. Borlongan
-
Interleukin-1 Receptor Antagonist as Therapy for Traumatic Brain Injury Neurotherapeutics (IF 5.7) Pub Date : 2023-08-23 Caroline Lindblad, Elham Rostami, Adel Helmy
-
Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY) Neurotherapeutics (IF 5.7) Pub Date : 2023-08-23 Clara G. Chisari, Assunta Bianco, Vincenzo Brescia Morra, Massimiliano Calabrese, Fioravante Capone, Paola Cavalla, Carlotta Chiavazza, Cristoforo Comi, Maura Danni, Massimo Filippi, Pietro Iaffaldano, Roberta Lanzillo, Salvatore Lo Fermo, Alessandra Lucisano, Alessandra Lugaresi, Giacomo Lus, Gerolama Alessandra Marfia, Fabiana Marinelli, Massimiliano Mirabella, Lucia Moiola, Chiara Perin, Sabrina
-
Dihydromyricetin Alleviates Ischemic Brain Injury by Antagonizing Pyroptosis in Rats Neurotherapeutics (IF 5.7) Pub Date : 2023-08-21 Huiru Ding, Quancheng Cheng, Xuan Fang, Ziyuan Wang, Jinyu Fang, Huaicun Liu, Junwei Zhang, Chunhua Chen, Weiguang Zhang
-
Fecal Microbiota Transplantation from Aged Mice Render Recipient Mice Resistant to MPTP-Induced Nigrostriatal Degeneration Via a Neurogenesis-Dependent but Inflammation-Independent Manner Neurotherapeutics (IF 5.7) Pub Date : 2023-08-18 Chen-Meng Qiao, Yu Zhou, Wei Quan, Xiao-Yu Ma, Li-Ping Zhao, Yun Shi, Hui Hong, Jian Wu, Gu-Yu Niu, Yu-Nuo Chen, Shan Zhu, Chun Cui, Wei-Jiang Zhao, Yan-Qin Shen
-
The Role of Clinical Assessment in the Era of Biomarkers Neurotherapeutics (IF 5.7) Pub Date : 2023-08-18 Arenn F. Carlos, Keith A. Josephs
-
N-Acetylcysteine and Probenecid Adjuvant Therapy for Traumatic Brain Injury Neurotherapeutics (IF 5.7) Pub Date : 2023-08-18 Robert S. B. Clark, Philip E. Empey, Patrick M. Kochanek, Michael J. Bell
-
ApoE Mimetic Peptides as Therapy for Traumatic Brain Injury Neurotherapeutics (IF 5.7) Pub Date : 2023-08-17 Daniel T. Laskowitz, David W. Van Wyck
-
Cyclosporine as Therapy for Traumatic Brain Injury Neurotherapeutics (IF 5.7) Pub Date : 2023-08-10 Magnus J. Hansson, Eskil Elmér
-
Lessons Learned in Time-Is Neurodegeneration Still Something Unpredictable? Neurotherapeutics (IF 5.7) Pub Date : 2023-08-11 William T Hu
-
Dimethyl Fumarate or Teriflunomide for Relapsing–Remitting Multiple Sclerosis: A Meta-analysis of Post-marketing Studies Neurotherapeutics (IF 5.7) Pub Date : 2023-08-01 Luca Prosperini, Shalom Haggiag, Serena Ruggieri, Carla Tortorella, Claudio Gasperini
-
Olaparib Attenuates Demyelination and Neuroinflammation in an Organotypic Slice Culture Model of Metachromatic Leukodystrophy Neurotherapeutics (IF 5.7) Pub Date : 2023-07-31 Marianna Mekhaeil, Melissa Jane Conroy, Kumlesh Kumar Dev
-
Increasing Rigor of Preclinical Research to Maximize Opportunities for Translation Neurotherapeutics (IF 5.7) Pub Date : 2023-07-31 Hannah L. Radabaugh, Adam R. Ferguson, Helen M. Bramlett, W. Dalton Dietrich